First Tracks Biotherapeutics Inc Stock (TRAX) Forecast
The First Tracks Biotherapeutics Inc (TRAX) stock price forecast for the next 30 days is generally positive, with an average analyst price target of $51.12, representing a +12.51% increase from the current price of $45.43. The highest analyst price target is $54.43, and the lowest is $47.80.
Disclaimer: The information on this page is not intended to be financial advice. It is for general information only and should not be used to make any investment decisions. Please consult with a professional financial advisor before making any investment decisions.
12-Month TRAX Price Target
Average 102.46 (+125.53% Upside)
Is First Tracks Biotherapeutics Inc (TRAX) A Buy Now?
Oscillators
Buy: 2 · Sell: 0 · Neutral: 5Summary: Neutral
Moving Averages
Buy: 9 · Sell: 1 · Neutral: 0Summary: Buy
According to our latest analysis, TRAX could be considered a Strong Buy, with 17 technical analysis indicators signaling 11 Buy signals, 1 signaling Sell signals and 5 Neutral signals. This might be a good time to open fresh positions on TRAX, as trading bullish markets is always a lot easier
- RSI (Relative Strength Index): The RSI(14) value of 60.23 indicates that TRAX is neither overbought nor oversold. It suggests a neutral sentiment in the short term.
- STOCH (Stochastic Oscillator): The STOCH value of 72.68 indicates that TRAX is neither overbought nor oversold. It indicates a balanced market sentiment without any extreme buying or selling pressure.
- STOCHRSI (Stochastic Relative Strength Index): The STOCHRSI value of 39.50 indicates that TRAX is neither overbought nor oversold. It indicates a balanced market sentiment without any extreme buying or selling pressure.
- ADX (Average Directional Index): The ADX value of 37.57 suggests an extremely strong trend in the market. Such high values are relatively rare and indicate a very robust directional movement.
- CCI (Commodity Channel Index): A CCI(14) value of 29.13 indicates that TRAX is not in oversold or overbought territory. It suggests a neutral sentiment in the short term.
Long-term TRAX price forecast for 2026, 2030, 2035, 2040, 2045 and 2050
Based on our analysis about First Tracks Biotherapeutics Inc financial reports and earnings history, First Tracks Biotherapeutics Inc (TRAX) stock could reach $452.04 by 2030, $1,523.71 by 2040 and $2,595.38 by 2050. See the projected annual prices until 2050 of the First Tracks Biotherapeutics Inc stock below:
- First Tracks Biotherapeutics Inc (TRAX) is expected to reach an average price of $723.77 in 2035, with a high prediction of $987.88 and a low estimate of $396.57. This indicates an +1,493% change from the last recorded price of $45.43.
- First Tracks Biotherapeutics Inc (TRAX) stock is projected to chart a bullish course in 2040, with an average price target of $989.00, representing an +2,077% change from its current level. The forecast ranges from a conservative $614.73 to a sky-high $1,523.71.
- Our analysts predict First Tracks Biotherapeutics Inc (TRAX) to change +2,477% by 2045, soaring from $832.89 to an average price of $1,170.76, potentially reaching $2,059.54. While $832.89 is the low estimate, the potential upside is significant.
- First Tracks Biotherapeutics Inc (TRAX) stock is expected to climb by 2050, reaching an average of $1,322.69, a +2,811% change from its current level. However, a wide range of estimates exists, with high and low targets of $2,595.38 and $1,051.05, respectively, highlighting the market's uncertainty.
First Tracks Biotherapeutics Inc Stock (TRAX) Year by Year Forecast
First Tracks Biotherapeutics Inc Stock (TRAX) Price Forecast for 2026
The predicted value for First Tracks Biotherapeutics Inc (TRAX) in 2026 is set at an average of $36.54. Estimates vary from a peak of $54.86 to a trough of $14.72, indicating an -19.57% surge from the present price of $45.43.
First Tracks Biotherapeutics Inc Stock (TRAX) Price Forecast for 2027
For 2027, Stockscan's Analyst expects the average price target for First Tracks Biotherapeutics Inc (TRAX) is $103.94, with a high forecast of $158.83 and a low forecast of $52.53. This indicates an +128.80% increase from the last price of $45.43.
First Tracks Biotherapeutics Inc Stock (TRAX) Price Forecast for 2028
In 2028, First Tracks Biotherapeutics Inc (TRAX) is projected to reach an average price of $173.87, with a high projection of $251.11 and a low estimate of $96.60. This indicates an +282.72% rise from the last price of $45.43.
First Tracks Biotherapeutics Inc Stock (TRAX) Price Forecast for 2029
The 2029 price forecast for First Tracks Biotherapeutics Inc Stock (TRAX) is $267.76 on average, with a high prediction of $385.07 and a low estimate of $151.14. This represents an +489.40% increase from the previous price of $45.43.
First Tracks Biotherapeutics Inc Stock (TRAX) Price Forecast for 2030
First Tracks Biotherapeutics Inc Stock (TRAX) is expected to reach an average price of $304.83 in 2030, with a high forecast of $452.04 and a low forecast of $178.41. This signifies an +570.98% surge from the last price of $45.43.
